Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

imiglucerase

Known as: imiglucerase [Chemical/Ingredient] 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
BACKGROUND The mainstay of treatment for Gaucher's disease type 1 is alternate-week infusion of enzyme replacement therapy (ERT… Expand
Highly Cited
2011
Highly Cited
2011
BACKGROUND In Gaucher disease (GD), acid-β-glucosidase (GBA1) gene mutations result in defective glucocerebrosidase and variable… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Highly Cited
2010
Highly Cited
2010
Gaucher disease is the first lysosomal disorder for which clinically effective enzyme replacement therapy has been introduced… Expand
Highly Cited
2008
Highly Cited
2008
Progressive skeletal disease accounts for some of the most debilitating complications of type 1 Gaucher disease. In this 48‐month… Expand
Highly Cited
2008
Highly Cited
2008
To assess the extent to which patients with type 1 Gaucher disease (GD1) receiving individualized enzyme replacement therapy with… Expand
Highly Cited
2007
Highly Cited
2007
The effect of ERT with imiglucerase on BMD in type 1 GD was studied using BMD data from the International Collaborative Gaucher… Expand
Review
2007
Review
2007
BACKGROUND Gaucher disease is a lysosomal storage disorder resulting from a deficiency of the lysosomal enzyme glucocerebrosidase… Expand
2004
2004
We have recently demonstrated that incubation of cultured rat hippocampal neurons with conduritol β-epoxide (CBE), an inhibitor… Expand
Review
2004
Review
2004
N-Butyldeoxynojirimycin (NB-DNJ, miglustat 'Zavesca') is an orallyactive iminosugar which inhibits the biosynthesis of… Expand
Highly Cited
1995
Highly Cited
1995
Gaucher's disease, the most common sphingolipidosis, is caused by deficiency of the lysosomal enzyme glucocerebrosidase. Therapy… Expand